Yuandong Biology: Benzenesulfonyl Gabapentin Tablets Obtained Drug Registration Certificate

Yuan Dong Biology announced that the company recently received the Benzylsulfonic Mirogabalin Tablets "Drug Registration Certificate" approved and issued by the National Medical Products Administration. This drug is used for the treatment of diabetic peripheral neuropathic pain in adults and belongs to the category B of the "National Basic Medical Insurance, Work-related Injury Insurance and Maternity Insurance Drug Catalog". The Benzylsulfonic Mirogabalin Tablets were originally developed by Daiichi Sankyo Co., Ltd. and were approved for marketing in China on June 28, 2024, with specifications of 2.5mg and 5mg, under the brand name Tarlige/Delicle. The National Medical Products Administration's official website shows that a domestically produced generic drug from Nanjing Jingdai Tianqing has been approved for marketing, considered to have passed bioequivalence assessment. The company is the second domestic generic drug company to have been approved for marketing and considered to have passed bioequivalence assessment.